labetuzumab govitecan (IMMU-130)

News alerts, weekly reports and conference planners

Company:

Gilead

Drug class:

Topoisomerase I inhibitor, CEACAM5-targeted antibody-drug conjugate

CEACAM5 expression	Neuroendocrine Tumor	CEACAM5 expression	Neuroendocrine Tumor	IMMU-130 Sensitive: D – Preclinical IMMU-130 Sensitive : D	IMMU-130 Sensitive: D – Preclinical IMMU-130 Sensitive : D
CEACAM5 expression	Prostate Cancer	CEACAM5 expression	Prostate Cancer	IMMU-130 Sensitive: D – Preclinical IMMU-130 Sensitive : D	IMMU-130 Sensitive: D – Preclinical IMMU-130 Sensitive : D

Associations
(2)